A Phase I/II, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Anti-Lymphoma Agents in Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas R/R NHL

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT03930953

Study #:
STUDY00149232

Start Date:
Apr 02, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03930953

View Complete Trial Details & Eligibility at ClinicalTrials.gov